Gulati, K. ., Wijndaele, K. ., Webb, J. ., von Arx, L. B., Seif, M. ., Jennison, T. ., … Khunti, K. . (2025). Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study. Diabetes Obes Metab. http://doi.org/10.1111/dom.16201
J. Webb
First name
J.
Last name
Webb
von Arx, L. B., Rachman, J. ., Webb, J. ., Casey, C. ., Patel, A. ., Diomatari, C. ., … Idris, I. . (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985
Spanopoulos, D. ., Okhai, H. ., Zaccardi, F. ., Tebboth, A. ., Barrett, B. ., Busse, M. ., … Khunti, K. . (2019). Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.13734
Spanopoulos, D. ., Busse, M. ., Webb, J. ., Tebboth, A. ., Gollop, N. D., & Marcus, M. W. (2019). DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice. Clin Ther. http://doi.org/10.1016/j.clinthera.2019.05.010
Webb, J. ., Mount, J. ., von Arx, L. B., Rachman, J. ., Spanopoulos, D. ., Wood, R. ., … Idris, I. . (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580